Safety and tolerability of subcutaneous trastuzumab for the adjuvant treatment of human epidermal growth factor receptor 2-positive early breast cancer: SafeHer phase III study's primary analysis of 2573 patients
Joseph Gligorov(Sorbonne Université), Luis Matamala(Fundación Arturo López Pérez), Andrew Redfern(Uppsala University Hospital), D. Cascallar, Gary Richardson(Cabrini Hospital), N. Al-Sakaff(Roche (Switzerland)), Jose Alberto Lopes Nogueira, Ani Zlatareva-Petrova, Roberto Hegg, Vinod Ganju(Peninsula Health), K. Patterson, Michael Friedländer(Prince of Wales Hospital), Christine Brezden‐Masley(Mount Sinai Hospital), Álvaro Edson Ramos Lessa(Hospital Santa Izabel), Michelino De Laurentiis(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Alejandro Andres Acevedo Gaete, Beyhan Ataseven(Kliniken Essen-Mitte), Anil A. Joy(University of Alberta), Mark Verrill(Newcastle upon Tyne Hospitals NHS Foundation Trust), Antoaneta Tomova, Patricia Bastick(Port Macquarie Base Hospital), Ori Freedman, Gustavo Ismael, Xavier Pivot(Levi Strauss (United States)), Kyung Hae Jung(University of Ulsan), Jamil Asselah, Maya Tsakova, Catherine Prady, Timur Cerić, Max S. Mano, Jane Beith(The University of Sydney), Dhurata Koroveshi, Alessandra Morelle, Stephen Chia(BC Cancer Agency), K. Timcheva, Kecman Malcic Gordana, Swati Kulkarni(Northwestern University), M.L. Casalnuovo, Michael Green(Children's Hospital of Pittsburgh), Ernesto Korbenfeld(Harbin Medical University), Mona Shing(Center for Global Development), Vanessa Helena, Hamdy A. Azim(Cairo University), Carlos Beato, Kamel Bouzid, Maree Colosimo, M. Ferrari, Hazem Assi(American University of Beirut Medical Center), Mohammed Harb(Moncton Hospital), Sabine Lauer(Roche (Switzerland))
Cited by 47
Related Papers
Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer
|New England Journal of Medicine|2018|2.9k
Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial
|The Lancet Oncology|2018|2.5k